Table Info

Table 1.

Active clinical trials for laryngeal cancer with immune checkpoint inhibitors (ICIs) that are no longer recruiting [26]

Trial identifier	Number of cancer patients	Intervention/Treatment regimen	Setting	Primary outcome(s)	Secondary outcome(s)
NCT04943445	43 laryngeals	Pembrolizumab-based therapy	Neoadjuvant (organ preservation)	Two-year laryngectomy-free survival	Two-year larynx dysfunction-free survival (alive without local recurrence or laryngoesophageal dysfunction)
NCT04030455	27 laryngeals	Cisplatin, docetaxel, pembrolizumab	Neoadjuvant	Disease control rate, pathological complete response rate	Incidence of adverse events, laryngeal preservation rate, relapse-free survival, overall survival, patient-reported quality of life
NCT04590963	370 head and neck (laryngeal unspecified)	Monalizumab, cetuximab	Recurrent/Metastatic	Overall survival in HPV-unrelated analysis set	Overall survival in full analysis set, progression-free survival, duration of response
NCT02586207	59 head and neck (laryngeal unspecified)	Pembrolizumab + chemoradiotherapy (CRT)	Neoadjuvant	Safety & tolerability	Efficacy, response rate
NCT03082534	78 head and neck (laryngeal unspecified)	Pembrolizumab + cetuximab	Recurrent/Metastatic	Clinical efficacy	Progression-free survival, overall survival, duration of response
NCT04576091	7 head and neck (laryngeal unspecified)	Pembrolizumab + radiation + BAY 1895344 (elimusertib)	Recurrent	Safety & tolerability	Incidence of adverse events, locoregional control, progression-free survival, overall response rate, 1-year overall survival, quality of life
NCT03370276	95 head and neck (laryngeal unspecified)	Cetuximab + nivolumab	Recurrent/Metastatic	Phase I: maximum tolerated dose, Phase II: overall survival	Overall response rate, progression-free survival, treatment-related adverse events
NCT03468218	36 head and neck (laryngeal unspecified)	Pembrolizumab + cabozantinib	Recurrent/Metastatic	Overall response rate	Progression-free survival

Declarations

Author contributions

MA: Investigation, Writing—original draft. PS: Conceptualization, Writing—original draft. GA, IA, NK, and EK: Writing—review & editing. NSM: Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Huang J, Chan SC, Ko S, Lok V, Zhang L, Lin X, et al. Updated disease distributions, risk factors, and trends of laryngeal cancer: a global analysis of cancer registries. Int J Surg. 2024;110:810–9. [DOI] [PubMed] [PMC]

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. [DOI] [PubMed]

Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, et al. Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. Am J Epidemiol. 2007;165:814–20. [DOI] [PubMed]

Yang D, Shi Y, Tang Y, Yin H, Guo Y, Wen S, et al. Effect of HPV Infection on the Occurrence and Development of Laryngeal Cancer: A Review. J Cancer. 2019;10:4455–62. [DOI] [PubMed] [PMC]

Ferlito A, Silver CE, Zeitels SM, Rinaldo A. Evolution of laryngeal cancer surgery. Acta Otolaryngol. 2002;122:665–72. [DOI] [PubMed]

Baird BJ, Sung CK, Beadle BM, Divi V. Treatment of early-stage laryngeal cancer: A comparison of treatment options. Oral Oncol. 2018;87:8–16. [DOI] [PubMed]

Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44. [DOI] [PubMed] [PMC]

Prasad V, Kaestner V. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017;44:132–5. [DOI] [PubMed]

Pembrolizumab (KEYTRUDA) [Internet]. US Food and Drug Administration; [cited 2025 Jan 15]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda

10.

Nivolumab for SCCHN [Internet]. US Food and Drug Administration; [cited 2025 Jan 15]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn

11.

Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol. 2022;13:388–411. [DOI] [PubMed] [PMC]

12.

Gupta I, Hussein O, Sastry KS, Bougarn S, Gopinath N, Chin-Smith E, et al. Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications. Adv Cancer Biol Metastasis. 2023;8:100107. [DOI]

13.

Granier C, Guillebon ED, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2:e000213. [DOI] [PubMed] [PMC]

14.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61. [DOI] [PubMed] [PMC]

15.

Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer. 2021;12:2735–46. [DOI] [PubMed] [PMC]

16.

Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39:98–106. [DOI] [PubMed] [PMC]

17.

Garden AS. The larynx and hypopharynx. In: Cox JD, Kian Ang K, editors. Radiation Oncology (9th ed. ). Mosby; 2010. pp. 282–308.

18.

Benner A, Sharma P. Anatomy, Head and Neck: Cervical, Respiratory, Larynx, and Cricoarytenoid. Sharma S, editor. Treasure Island (FL): StatPearls Publishing; 2025. [PubMed]

19.

Rees LEN, Jones PH, Ayoub O, Gunasekaran S, Rajkumar K, Stokes CR, et al. Smoking influences the immunological architecture of the human larynx. Clin Immunol. 2006;118:342–7. [DOI] [PubMed]

20.

Jetté M. Toward an Understanding of the Pathophysiology of Chronic Laryngitis. Perspect ASHA Spec Interest Groups. 2016;1:14–25. [DOI] [PubMed] [PMC]

21.

Thibeault SL, Rees L, Pazmany L, Birchall MA. At the crossroads: mucosal immunology of the larynx. Mucosal Immunol. 2009;2:122–8. [DOI] [PubMed] [PMC]

22.

Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22:223–30. [DOI] [PubMed] [PMC]

23.

Karpathiou G, Dumollard JM, Peoc’h M. Laryngeal Tumor Microenvironment. Adv Exp Med Biol. 2020;1296:79–101. [DOI] [PubMed]

24.

Johns MM, Kolachala V, Berg E, Muller S, Creighton FX, Branski RC. Radiation fibrosis of the vocal fold: from man to mouse. Laryngoscope. 2012;122:S107–25. [DOI] [PubMed] [PMC]

25.

Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;12:16. [DOI] [PubMed] [PMC]

26.

Clinicaltrials.gov [Internet]. Bethesda: National Library of Medicine; [cited 2025 Jan 15]. Available from: https://clinicaltrials.gov/

27.

Luginbuhl A, Johnson JM, Scott ER, Harshyne L, Flerova EF, Tuluc M, et al. Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes. J Clin Oncol. 2022;40:6070. [DOI]

28.

Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22:450–62. [DOI] [PubMed]

29.

Ferris RL, Jr GB, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856–67. [DOI] [PubMed] [PMC]

30.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65. [DOI] [PubMed]

31.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, et al.; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. Erratum in: Lancet. 2020;395:272. Erratum in: Lancet. 2020;395:564. Erratum in: Lancet. 2021;397:2252. [DOI] [PubMed]

32.

Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the Phase III KEYNOTE-048 study. J Clin Oncol. 2023;41:790–802. [DOI] [PubMed] [PMC]

33.

Frankart AJ, Sadraei NH, Huth B, Redmond KP, Barrett WL, Kurtzweil N, et al. A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer. Laryngoscope Investig Otolaryngol. 2022;7:437–43. [DOI] [PubMed] [PMC]

34.

Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, et al. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021;13:2882. [DOI] [PubMed] [PMC]

35.

Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial. Clin Cancer Res. 2020;26:5140–52. Erratum in: Clin Cancer Res. 2021;27:357. [DOI] [PubMed] [PMC]

36.

Hanna GJ, O’Neill A, Shin KY, Wong K, Jo VY, Quinn CT, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. Clin Cancer Res. 2022;28:468–78. [DOI] [PubMed] [PMC]

37.

Ferris RL, Moskovitz J, Kunning S, Ruffin AT, Reeder C, Ohr J, et al. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2022;28:1335–44. [DOI] [PubMed] [PMC]

38.

Johnson JM, Vathiotis IA, Harshyne LA, Ali A, Ad VB, Axelrod R, et al. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. J Immunother Cancer. 2023;11:e007141. [DOI] [PubMed] [PMC]

39.

Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84:101977. [DOI] [PubMed]

40.

Bill R, Faquin WC, Pai SI. Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations. Head Neck Pathol. 2023;17:969–75. [DOI] [PubMed] [PMC]

41.

Rodrigo JP, Sánchez-Canteli M, Otero-Rosales M, Martínez-Camblor P, Hermida-Prado F, García-Pedrero JM. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis. J Transl Med. 2024;22:135. [DOI] [PubMed] [PMC]

42.

Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius IR, Johannesen HH, Fischer BM, et al. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer. 2019;120:1003–6. [DOI] [PubMed] [PMC]

43.

Goetz JW, Rabinowits G, Kalman N, Villa A. A Review of Immunotherapy for Head and Neck Cancer. J Dent Res. 2024;103:1185–96. [DOI] [PubMed]

44.

Davis RJ, Waes CV, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59–70. [DOI] [PubMed] [PMC]

45.

Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. Erratum in: J Hematol Oncol. 2023;16:105. [DOI] [PubMed] [PMC]

46.

Dougan M. Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunol Res. 2020;8:1230–5. [DOI] [PubMed] [PMC]

47.

Postow MA, Hellmann MD. Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:1165. [DOI] [PubMed]

48.

Dang S, Li X, Liu H, Zhang S, Li W. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis. Cancer Med. 2024;13:e7119. [DOI] [PubMed] [PMC]

49.

Wang DY, Salem J, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4:1721–8. Erratum in: JAMA Oncol. 2018;4:1792. [DOI] [PubMed] [PMC]

50.

Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, et al. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol. 2022;13:804597. [DOI] [PubMed] [PMC]

51.

Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019;7:226. [DOI] [PubMed] [PMC]

52.

Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25:551–7. [DOI] [PubMed]

53.

Homer JJ, Fardy MJ. Surgery in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S68–70. Erratum in: J Laryngol Otol. 2016;130:792. [DOI] [PubMed] [PMC]

54.

Zotta A, Marciano ML, Sabbatino F, Ottaiano A, Cascella M, Pontone M, et al. Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach. Biomedicines. 2024;12:2337. [DOI] [PubMed] [PMC]

55.

Runnels J, Bloom JR, Hsieh K, Dickstein DR, Shi Y, Jones BM, et al. Combining Radiotherapy and Immunotherapy in Head and Neck Cancer. Biomedicines. 2023;11:2097. [DOI] [PubMed] [PMC]

56.

Sindhu SK, Bauman JE. Current Concepts in Chemotherapy for Head and Neck Cancer. Oral Maxillofac Surg Clin North Am. 2019;31:145–54. [DOI] [PubMed] [PMC]

57.

Vallianou NG, Evangelopoulos A, Kounatidis D, Panagopoulos F, Geladari E, Karampela I, et al. Immunotherapy in Head and Neck Cancer: Where Do We Stand? Curr Oncol Rep. 2023;25:897–912. [DOI] [PubMed]